CLINICAL TRIALS PROFILE FOR ABARELIX
✉ Email this page to a colleague
All Clinical Trials for abarelix
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00100243 ↗ | Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy | Completed | PRAECIS Pharmaceuticals Inc. | Phase 2 | 2004-05-01 | This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg). |
NCT00841113 ↗ | Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer | Completed | Speciality European Pharma Limited | Phase 3 | 1999-01-01 | To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for abarelix
Condition Name
Clinical Trial Locations for abarelix
Trials by Country
Clinical Trial Progress for abarelix
Clinical Trial Phase
Clinical Trial Sponsors for abarelix
Sponsor Name